LEASE AGREEMENTLease Agreement • February 12th, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this 15th day of December, 2019, between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company (“Landlord”), and ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation (“Tenant”).
RESTRICTED STOCK UNIT AGREEMENT (EMPLOYEES)Restricted Stock Unit Agreement • February 12th, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units (the “Restricted Stock Units”) granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Grantee”) pursuant to and subject to the terms of the Ultragenyx Pharmaceutical Inc. Employment Inducement Plan (as amended from time to time, the “Plan”), which is incorporated herein by reference.
Number of Shares of Stock subject to Stock Option: [-] Price Per Share: $[-] Date of Grant: [-] Vesting Start Date: [-] ULTRAGENYX PHARMACEUTICAL INC. Employment Inducement Plan NON-STATUTORY STOCK OPTION AGREEMENT (EMPLOYEES) (ex-U.S.) This agreement...Non-Statutory Stock Option Agreement • February 12th, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
RESTRICTED STOCK UNIT AGREEMENT (EMPLOYEES) (ex-U.S.)Restricted Stock Unit Agreement • February 12th, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units (the “Restricted Stock Units”) granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Grantee”) pursuant to and subject to the terms of the Ultragenyx Pharmaceutical Inc. Employment Inducement Plan (as amended from time to time, the “Plan”), which is incorporated herein by reference.
FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • February 12th, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “First Amendment”) is made as of September 30, 2020, by and between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company (“Landlord”), and ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation (“Tenant”).
SECOND AMENDMENT TO LEASE AGREEMENTLease Agreement • February 12th, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) is made as of October 21, 2020, by and between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company (“Landlord”), and ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation (“Tenant”).
Non-statutory Stock Option Agreement (Employees)Non-Statutory Stock Option Agreement • February 12th, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a stock option granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Optionee”) pursuant to and subject to the terms of the Ultragenyx Pharmaceutical Inc. Employment Inducement Plan (as amended from time to time, the “Plan”), which is incorporated herein by reference.
AMENDMENT LICENSE AGREEMENTLicense Agreement • February 12th, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This Amendment to the License Agreement (“Amendment”) is made and entered into by and between Ultragenyx Pharmaceutical Inc., a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 60 Leveroni Court, Novato, CA 94949 (“ Ultragenyx”), and Baylor Research Institute, a non-profit corporation organized and existing under the laws of the State of Texas, having its principal place of business at 3310 Live Oak Street, Suite 501, Dallas, Texas 75204 (“BRI ”).
ContractMaster Services Agreement • February 12th, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED
License AgreementLicense Agreement • February 12th, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
